Na-agbasa nnukwu lymphoma B-cell (DLBCL) -04

Mazị Li, onye dị afọ 64 (pseudonym), achọpụtara na ọ nwere nnukwu lymphoma B-cell (DLBCL) na-agbasa afọ anọ gara aga, bụ nke gara n'ihu na itinye aka na njedebe nke splin, ribs, ngụgụ, na pleura, nkewapụtara dị ka ọkwa IV. . Na-eso usoro ọgwụgwọ immunochemotherapy nke mbụ, ọnọdụ ya nọgidere na-agbaghara ihe karịrị afọ atọ. Otú ọ dị, na March nke afọ gara aga, ọrịa ya laghachiri, gụnyere ọtụtụ ọnụọgụ lymph retroperitoneal. N'agbanyeghị chemotherapy salvage nke abụọ, ọ na-enweta mgbaghara nke obere ma na-emebi ngwa ngwa, na-achọ ọgwụgwọ dị irè karị iji chịkwaa ọganihu ọzọ.

N'ịbụ ndị chere ihe ịma aka a dị egwu ihu, ndị ọkachamara na ụlọ ọgwụ Lu Daopei nyochara nke ọma okwu Mr. Li wee kpọkọta ndị otu multidisciplinary (MDT) iji kwado ọgwụgwọ cell CAR-T. Usoro ọgwụgwọ cell CAR-T, dị ka ụdị ọhụrụ nke tumor immunotherapy, na-enye uru dị ukwuu dị ka nlebara anya siri ike na ịrụ ọrụ na-adịgide adịgide maka ndị ọrịa nwere lymphoma nlọghachi azụ na refractory.

Na Jenụwarị 2023, Maazị Li nwetara ọgwụgwọ cell CAR-T na Ngalaba Lymphoma. Tupu ọgwụgwọ, ọ gara biopsy nke akụkụ lymph inguinal ziri ezi, nke kwadoro CD19 na CD20 positivity, na-enye ebumnuche doro anya maka ọgwụgwọ cell CAR-T. N'okpuru nduzi nke Prọfesọ Li, ndị otu ahụike chepụtara atụmatụ ọgwụgwọ ahaziri onwe ya.

Na Julaị 25, 2023, Maazị Li mezuru usoro infusion nke mkpụrụ ndụ CD19/20 CAR-T, bụ nke gara n'ihu nke ọma site n'aka ndị otu ahụike na-enyocha ya nke ọma. N'agbanyeghị na-enwe cytokine release syndrome, cytopenia, na ọrịa ihe ize ndụ mgbe infusion, stringent nkwado nlekọta jisiri ike ọjọọ mmeghachi omume n'oge ọgwụgwọ.

Ọnwa isii ka emechara usoro ọgwụgwọ CAR-T cell, Maazị Li egosighi ọnya na-arụsi ọrụ ike n'ahụ ya niile, na-enweta nzaghachi metabolic zuru oke (CMR), nke wetara olileanya ọhụrụ maka ahụike ya. Ndị otu ahụike na-agbakwunye ọnya retroperitoneal fọdụrụnụ na ọgwụgwọ redio iji hụ na nlọghachi ọrịa zuru oke na nkwụsi ike ogologo oge.

Site na immunotherapy cell CAR-T a, Maazị Li ọ bụghị naanị nweta nkwalite dị ukwuu na ọnọdụ ya kamakwa ọ nwetaghachiri ntụkwasị obi na ume ndụ na ndụ. Okwu ya na-enye olile anya na ntụzịaka ọhụrụ maka ndị ọrịa lymphoma ma gosipụta ikike na ịdị irè nke ọgwụgwọ cell CAR-T n'ịgwọ lymphoma refractory.

Usoro ọgwụgwọ cell CAR-T, dị ka ọgwụgwọ ọrịa cancer ọhụrụ, na-agbanwe ọnọdụ ndụ nke ndị ọrịa nwere lymphoma refractory. N'okpuru nlekọta nke ọma nke ndị otu ọkachamara na Ngalaba Lymphoma, ọtụtụ ndị ọrịa dịka Maazị Li nwere ike ịtụ anya mmelite dị ịrịba ama na nlanarị na ịdị mma nke ndụ. Na-ele anya n'ihu, ọganihu na ngwa nke ọgwụgwọ cell CAR-T na-ekwe nkwa atụmanya sara mbara na ohere na ọgwụgwọ ọrịa cancer.